Mission Wealth Management LP Sells 172 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Mission Wealth Management LP trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,984 shares of the medical research company’s stock after selling 172 shares during the quarter. Mission Wealth Management LP’s holdings in Thermo Fisher Scientific were worth $2,114,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in TMO. Accurate Wealth Management LLC grew its position in Thermo Fisher Scientific by 6.3% during the third quarter. Accurate Wealth Management LLC now owns 553 shares of the medical research company’s stock valued at $268,000 after buying an additional 33 shares during the period. Vicus Capital bought a new position in shares of Thermo Fisher Scientific in the third quarter worth approximately $344,000. Cambridge Investment Research Advisors Inc. boosted its position in shares of Thermo Fisher Scientific by 16.3% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 43,128 shares of the medical research company’s stock worth $21,830,000 after purchasing an additional 6,055 shares during the period. Kingswood Wealth Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 14.2% in the third quarter. Kingswood Wealth Advisors LLC now owns 995 shares of the medical research company’s stock worth $504,000 after purchasing an additional 124 shares during the period. Finally, Dakota Wealth Management boosted its position in shares of Thermo Fisher Scientific by 7.7% in the third quarter. Dakota Wealth Management now owns 5,779 shares of the medical research company’s stock worth $2,925,000 after purchasing an additional 414 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on TMO shares. Royal Bank of Canada upped their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Barclays upped their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 25th. Raymond James upped their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Finally, Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $607.35.

Thermo Fisher Scientific Stock Down 1.4 %

NYSE:TMO opened at $568.74 on Wednesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The stock has a market capitalization of $217.09 billion, a P/E ratio of 36.48, a P/E/G ratio of 2.40 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company’s 50-day simple moving average is $574.58 and its 200-day simple moving average is $531.67.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, beating the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.59 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at approximately $74,039,491.68. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of Thermo Fisher Scientific stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last ninety days, insiders sold 52,277 shares of company stock valued at $29,649,264. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.